Clinical utility of Firebird drug-eluting stent in the treatment of de novo native coronary artery lesions
- VernacularTitle:Firebird药物洗脱支架治疗冠状动脉原发病变
- Author:
Jun NI
;
Weifeng SHEN
;
Jiansheng ZHANG
- Publication Type:Journal Article
- Keywords:
Drug-eluting stent;
Coronary artery disease;
Interventional therapy
- From:
Journal of Interventional Radiology
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of Firebird drug-eluting stent (DES) in the treatment of de novo native coronary artery lesions.Methods 60 patients underwent coronary artery stenting with Firebird DES (Firebird group), 52 patients with Cypher DES (Cypher group) and another 20 patents with Mustang bare stents (Mustang group). The instant and short term follow-up outcomes were compared among the three groups. Results The procedural successful rates (98.3%vs 100.0%vs 100.0%), nitrate cessation (32.1%vs 33.3%vs 29.4% ), re-admission(5.6%vs8.3%vs11.7%) and follow-up rates (88.3%vs 92.3%vs 85.0%) did not significantly differ among the three groups. As compared with Firebird group, patients in Mustang group had more MACE(17.6%vs 0), higher occurrence rates of restenosis(17.6%vs 0) and target vessel revascularization(17.6%vs 0)(P
